Skip to main content
Explore URMC
URMC / Research / Clinical Trials / Study Details

UGUP17050 / Deepak Cisplatin Pilot IIT / Deepak Sahasrabudhe

Basic Study Information

It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Location: Wilmot Cancer Institute

Lead Researcher (Principal Investigator)

Lead Researcher:  Deepak Sahasrabudhe, MD

Study Contact Information

Study Coordinator: Amber Johnson

Additional Study Details

Return to Search